Olga Uspenskaya-Cadoz was appointed as Chief Medical Officer at VectorY Therapeutics in April 2025. Dr. Uspenskaya-Cadoz brings over two decades of expertise in neurology, gene therapy, and clinical development to VectorY. Within VectorY, she leads clinical and regulatory strategy as the company advances its pipeline of vectorized antibody therapies for neurodegenerative diseases.

Before joining VectorY, Dr. Uspenskaya-Cadoz was Vice President, Medical, Gene Therapy at Eli Lilly where she oversaw clinical development, pharmacovigilance, and patient advocacy for CNS and lysosomal storage genetic medicines. She also played a key role in shaping the company’s ALS and rare disease strategy. Previously, she served as Vice President of Clinical Development at Prevail Therapeutics, where she contributed to the design of novel gene therapy programs for neurodegenerative disorders.

Dr. Uspenskaya-Cadoz holds an M.D. and Ph.D. in Neurosciences from First Moscow State Medical University, with additional research training at Ludwig-Maximilians University in Munich and the Sorbonne University of Paris. She has authored over 20 peer-reviewed publications and has presented extensively at international scientific conferences.